Chemoquiescence for ideal cancer treatment and prevention: where are we now?
Identifieur interne : 000265 ( Ncbi/Curation ); précédent : 000264; suivant : 000266Chemoquiescence for ideal cancer treatment and prevention: where are we now?
Auteurs : Napapan Kangwan [Corée du Sud] ; Jong-Min Park [Corée du Sud] ; Eun-Hee Kim [Corée du Sud] ; Ki Baik Hahm [Corée du Sud]Source :
- Journal of cancer prevention [ 2288-3649 ] ; 2014.
Abstract
Cellular quiescence is a state of reversible cell cycle arrest and is associated with a low metabolic state featured with decreased glycolysis, reduced translation rates, and activation of autophagy, fundamentally to provide nutrients for cell survival similar as seen in hybernation. As signal for quiescence, inactivating the target of rapamycin kinase and resulting reduced cell growth and biosynthesis are essential, but cellular quiescence is not always associated with reduced metabolism since it is also possible to achieve a state of cellular quiescence in which glucose uptake, glycolysis and flux through central carbon metabolism are not reduced. However, in cancer cells, overcoming intrinsic and acquired resistance of cancer stem or cancer dormancy cells to current clinical treatments can be reversed with the acquisition of chemoquiesence. The development of new drug combinations or strategy to treat the highly aggressive and metastatic cancers including relapsed leukaemias, melanoma and head and neck, brain, lung, breast, ovary, prostate, pancreas as well as gastrointestinal cancers which remain incurable in the clinic in spite of aggressive therapies, can be accelerated with the introduction of chemoquiescence agent, for which cancer stem cells or tumor dormancy should be eradicated or removed. Recently potential applications of metformin or chloroquine as well as the potential drugs under investigation such as proton pump inhibitor, sonic hedgehog inhibitor, and Akt inhibitor, are actively investigated in this field of chemoquiescence to achieve cancer cure far beyond those of chemoprevention. In this review article, the evolving concept of chemoquiescence or cancer dormancy will be introduced accompanied by a description of novel target drug development.
DOI: 10.15430/JCP.2014.19.2.89
PubMed: 25337576
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000279
- to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :000279
- to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :000302
- to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :000265
Links to Exploration step
pubmed:25337576Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Chemoquiescence for ideal cancer treatment and prevention: where are we now?</title>
<author><name sortKey="Kangwan, Napapan" sort="Kangwan, Napapan" uniqKey="Kangwan N" first="Napapan" last="Kangwan">Napapan Kangwan</name>
<affiliation wicri:level="3"><nlm:affiliation>Cancer Prevention Research Center, CHA University School of Medicine, Seoul, Korea.</nlm:affiliation>
<country xml:lang="fr">Corée du Sud</country>
<wicri:regionArea>Cancer Prevention Research Center, CHA University School of Medicine, Seoul</wicri:regionArea>
<placeName><settlement type="city">Séoul</settlement>
<region type="capital">Région capitale de Séoul</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Park, Jong Min" sort="Park, Jong Min" uniqKey="Park J" first="Jong-Min" last="Park">Jong-Min Park</name>
<affiliation wicri:level="3"><nlm:affiliation>Cancer Prevention Research Center, CHA University School of Medicine, Seoul, Korea.</nlm:affiliation>
<country xml:lang="fr">Corée du Sud</country>
<wicri:regionArea>Cancer Prevention Research Center, CHA University School of Medicine, Seoul</wicri:regionArea>
<placeName><settlement type="city">Séoul</settlement>
<region type="capital">Région capitale de Séoul</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Kim, Eun Hee" sort="Kim, Eun Hee" uniqKey="Kim E" first="Eun-Hee" last="Kim">Eun-Hee Kim</name>
<affiliation wicri:level="3"><nlm:affiliation>Cancer Prevention Research Center, CHA University School of Medicine, Seoul, Korea.</nlm:affiliation>
<country xml:lang="fr">Corée du Sud</country>
<wicri:regionArea>Cancer Prevention Research Center, CHA University School of Medicine, Seoul</wicri:regionArea>
<placeName><settlement type="city">Séoul</settlement>
<region type="capital">Région capitale de Séoul</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Hahm, Ki Baik" sort="Hahm, Ki Baik" uniqKey="Hahm K" first="Ki Baik" last="Hahm">Ki Baik Hahm</name>
<affiliation wicri:level="3"><nlm:affiliation>Cancer Prevention Research Center, CHA University School of Medicine, Seoul, Korea.</nlm:affiliation>
<country xml:lang="fr">Corée du Sud</country>
<wicri:regionArea>Cancer Prevention Research Center, CHA University School of Medicine, Seoul</wicri:regionArea>
<placeName><settlement type="city">Séoul</settlement>
<region type="capital">Région capitale de Séoul</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2014">2014</date>
<idno type="RBID">pubmed:25337576</idno>
<idno type="pmid">25337576</idno>
<idno type="doi">10.15430/JCP.2014.19.2.89</idno>
<idno type="wicri:Area/PubMed/Corpus">000279</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000279</idno>
<idno type="wicri:Area/PubMed/Curation">000279</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000279</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000302</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000302</idno>
<idno type="wicri:Area/Ncbi/Merge">000265</idno>
<idno type="wicri:Area/Ncbi/Curation">000265</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Chemoquiescence for ideal cancer treatment and prevention: where are we now?</title>
<author><name sortKey="Kangwan, Napapan" sort="Kangwan, Napapan" uniqKey="Kangwan N" first="Napapan" last="Kangwan">Napapan Kangwan</name>
<affiliation wicri:level="3"><nlm:affiliation>Cancer Prevention Research Center, CHA University School of Medicine, Seoul, Korea.</nlm:affiliation>
<country xml:lang="fr">Corée du Sud</country>
<wicri:regionArea>Cancer Prevention Research Center, CHA University School of Medicine, Seoul</wicri:regionArea>
<placeName><settlement type="city">Séoul</settlement>
<region type="capital">Région capitale de Séoul</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Park, Jong Min" sort="Park, Jong Min" uniqKey="Park J" first="Jong-Min" last="Park">Jong-Min Park</name>
<affiliation wicri:level="3"><nlm:affiliation>Cancer Prevention Research Center, CHA University School of Medicine, Seoul, Korea.</nlm:affiliation>
<country xml:lang="fr">Corée du Sud</country>
<wicri:regionArea>Cancer Prevention Research Center, CHA University School of Medicine, Seoul</wicri:regionArea>
<placeName><settlement type="city">Séoul</settlement>
<region type="capital">Région capitale de Séoul</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Kim, Eun Hee" sort="Kim, Eun Hee" uniqKey="Kim E" first="Eun-Hee" last="Kim">Eun-Hee Kim</name>
<affiliation wicri:level="3"><nlm:affiliation>Cancer Prevention Research Center, CHA University School of Medicine, Seoul, Korea.</nlm:affiliation>
<country xml:lang="fr">Corée du Sud</country>
<wicri:regionArea>Cancer Prevention Research Center, CHA University School of Medicine, Seoul</wicri:regionArea>
<placeName><settlement type="city">Séoul</settlement>
<region type="capital">Région capitale de Séoul</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Hahm, Ki Baik" sort="Hahm, Ki Baik" uniqKey="Hahm K" first="Ki Baik" last="Hahm">Ki Baik Hahm</name>
<affiliation wicri:level="3"><nlm:affiliation>Cancer Prevention Research Center, CHA University School of Medicine, Seoul, Korea.</nlm:affiliation>
<country xml:lang="fr">Corée du Sud</country>
<wicri:regionArea>Cancer Prevention Research Center, CHA University School of Medicine, Seoul</wicri:regionArea>
<placeName><settlement type="city">Séoul</settlement>
<region type="capital">Région capitale de Séoul</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j">Journal of cancer prevention</title>
<idno type="ISSN">2288-3649</idno>
<imprint><date when="2014" type="published">2014</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Cellular quiescence is a state of reversible cell cycle arrest and is associated with a low metabolic state featured with decreased glycolysis, reduced translation rates, and activation of autophagy, fundamentally to provide nutrients for cell survival similar as seen in hybernation. As signal for quiescence, inactivating the target of rapamycin kinase and resulting reduced cell growth and biosynthesis are essential, but cellular quiescence is not always associated with reduced metabolism since it is also possible to achieve a state of cellular quiescence in which glucose uptake, glycolysis and flux through central carbon metabolism are not reduced. However, in cancer cells, overcoming intrinsic and acquired resistance of cancer stem or cancer dormancy cells to current clinical treatments can be reversed with the acquisition of chemoquiesence. The development of new drug combinations or strategy to treat the highly aggressive and metastatic cancers including relapsed leukaemias, melanoma and head and neck, brain, lung, breast, ovary, prostate, pancreas as well as gastrointestinal cancers which remain incurable in the clinic in spite of aggressive therapies, can be accelerated with the introduction of chemoquiescence agent, for which cancer stem cells or tumor dormancy should be eradicated or removed. Recently potential applications of metformin or chloroquine as well as the potential drugs under investigation such as proton pump inhibitor, sonic hedgehog inhibitor, and Akt inhibitor, are actively investigated in this field of chemoquiescence to achieve cancer cure far beyond those of chemoprevention. In this review article, the evolving concept of chemoquiescence or cancer dormancy will be introduced accompanied by a description of novel target drug development. </div>
</front>
</TEI>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Ncbi/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000265 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd -nk 000265 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= ChloroquineV1 |flux= Ncbi |étape= Curation |type= RBID |clé= pubmed:25337576 |texte= Chemoquiescence for ideal cancer treatment and prevention: where are we now? }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/RBID.i -Sk "pubmed:25337576" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd \ | NlmPubMed2Wicri -a ChloroquineV1
This area was generated with Dilib version V0.6.33. |